These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25622776)

  • 1. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
    Worley MJ; Shoptaw SJ; Bickel WK; Ling W
    Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
    Kaur AD; McQueen A; Jan S
    J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
    Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
    J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain.
    Griffin ML; McDermott KA; McHugh RK; Fitzmaurice GM; Jamison RN; Weiss RD
    Drug Alcohol Depend; 2016 Jun; 163():216-21. PubMed ID: 27161860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
    Weiss RD; Griffin ML; Potter JS; Dodd DR; Dreifuss JA; Connery HS; Carroll KM
    Drug Alcohol Depend; 2014 Jul; 140():118-22. PubMed ID: 24831754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
    Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
    Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prescription Opioid Addiction Treatment Study: What have we learned.
    Weiss RD; Rao V
    Drug Alcohol Depend; 2017 Apr; 173 Suppl 1(Suppl 1):S48-S54. PubMed ID: 28363320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
    Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.
    Dreifuss JA; Griffin ML; Frost K; Fitzmaurice GM; Potter JS; Fiellin DA; Selzer J; Hatch-Maillette M; Sonne SC; Weiss RD
    Drug Alcohol Depend; 2013 Jul; 131(1-2):112-8. PubMed ID: 23333292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.